TY - JOUR T1 - Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane JF - Drug Metabolism and Disposition JO - Drug Metab Dispos DO - 10.1124/dmd.118.081166 SP - dmd.118.081166 AU - Shaman Luo AU - Gang Chen AU - Cristina I. Truica AU - Cynthia C. Baird AU - Zuping Xia AU - Philip Lazarus Y1 - 2018/01/01 UR - http://dmd.aspetjournals.org/content/early/2018/09/26/dmd.118.081166.abstract N2 - Exemestane (EXE) is an aromatase inhibitor used for the prevention and treatment of estrogen receptor-positive breast cancer. Although the known major metabolic pathway for EXE is reduction to form the active 17β-dihydro-EXE (17β-DHE) and subsequent glucuronidation to 17β-hydroxy-EXE-17-O-β;-D-glucuronide (17β-DHE-Gluc), previous studies suggest that other major metabolites exist for exemestane. In the present study, a liquid chromatography-mass spectrometry (LC-MS) approach was used to acquire accurate mass data in MSE mode, in which precursor ion and fragment ion data was obtained simultaneously to screen novel phase II EXE metabolites in urine specimens from women taking EXE. Two major metabolites predicted to be cysteine conjugates of EXE and 17β-DHE by elemental composition were identified. The structures of the two metabolites were confirmed to be 6-methylcysteinylandrosta-1,4-diene-3,17-dione (6-EXE-cys) and 6-methylcysteinylandrosta-1,4-diene-17&#[beta]-hydroxy-3-one (6-17β-DHE-cys) after comparison to their chemically-synthesized counterparts. Both underwent biosynthesis in vitro in three stepwise enzymatic reactions with the first involving glutathione conjugation. The cysteine conjugates of EXE and 17β-DHE were subsequently quantified by LC-MS in the urine and matched plasma samples of 132 subjects taking EXE. The combined 6-EXE-cys plus 6-17β-DHE-cys made up 77% of total EXE metabolites in urine (versus 1.7, 1.4, and 21% for EXE, 17β-DHE, and 17β-DHE-Gluc, respectively) and 35% in plasma (versus 17, 12, and 36% for EXE, 17β-DHE, and 17β-DHE-Gluc, respectively). Therefore, cysteine conjugates of EXE and 17β-DHE appear to be major metabolites of EXE in both urine and plasma. ER -